AI-designed drug candidates are hitting 80-90% Phase I success rates versus a 50% historical average; poet Sasha Stiles' AI collaboration "A Living Poem" lands at MoMA; CoreWeave and Nebius flagged as potential doubles for 2026; Sam Altman compares AI training energy to raising a human child; and Demis Hassabis proposes the Einstein Test as a genuine benchmark for AGI.